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1. Identify indications and contraindications for CRRT and compare 
CRRT to intermittent dialysis therapy.
2. Discuss the importance of a multidisciplinary team approach to 
managing patients on CRRT.
3. Discuss the use of replacement fluids and dialysates in CRRT.
4. Describe pharmacy and nursing management during initiation and 
maintenance of CRRT.
5. Discuss potential complications of CRRT.
6. Discuss essential components of nursing and pharmacy care for 
patients receiving CRRT.
Objectives:
• What is Continuous Renal Replacement Therapy 
(CRRT)?
• CRRT was developed in 1980’s to provide 
artificial kidney support to patients who could 
not tolerate traditional hemodialysis.
• The use of CRRT has increased dramatically in 
recent years.
Introduction
• Usually led by a nephrologist.
• The team should include:
Critical care nurse
Dialysis nurse
Clinical pharmacist
Dietician
Clinical laboratory
Consulting physicians
The Multidisciplinary Team
• Intermittent therapies are performed every 2-3 days 
and last about 3-4 hours.
• During traditional hemodialysis treatment, large 
amounts of fluids, electrolytes and toxins are removed.
• Intermittent hemodialysis requires that patients’ 
protein and fluid intake be limited between treatments.
• CRRT addresses these needs by providing slow, 
continuous removal of toxins and fluids continuously 
over a 24-hour period.
Continuous vs. Intermittent Renal 
Replacement Therapy
CRRT Intermittent HD
Continuous Y N
Rapid change in 
electrolytes, pH, and 
fluid balance
N Y
Need to reduce dosage 
of renally cleared drugs
Depends Y
Need to adjust 
administration times of 
renally cleared drugs
N Y
Need to limit protein, 
potassium, and fluid 
intake
N Y
pH and electrolyte shifts 
after therapy
N Y
Continuous vs. Intermittent Renal 
Replacement Therapy
• Any patient who meets criteria for hemodialysis but 
cannot tolerate intermittent dialysis due to 
hemodynamic instability.
• Includes patients with:
Fluid overload
Acute renal failure
Chronic renal failure
Life-threatening electrolyte imbalance
Drug overdose
Major burns
Indications for CRRT
• Advance directives indicating the patient does 
not desire dialysis or life-sustaining therapy.
• Patient or family refusal of therapy.
• Inability to establish vascular access.
Contraindications for CRRT
Principles of Renal Replacement 
Therapy
1. Ultrafiltration
2. Convection
3. Adsorption
4. Diffusion
Vascular Access
• Venovenous is by far 
the most commonly 
used today.
• Common sites include 
the jugular, subclavian
and femoral veins.
Dialysate:  any fluid used on the opposite 
side of the filter from the blood.
• Typical flow rates are 600-1800ml/hr.
• Note:  sodium bicarbonate has a low 
compatibility with calcium.  If both are 
added to a bag in sufficient quantities, it 
will cause a precipitate and clog the filter!
Fluids Used in CRRT
Replacement Fluids:
• Used to increase the amount of solute that is removed 
in CRRT.
• They don’t actually REPLACE anything!
• Typical flow rates are 1000-2000ml/hr.
Total Parenteral Nutrition (TPN):
• Not actually part of CRRT, but is usually given 
concurrently.
Fluids Used in CRRT
Heparin
• Carries the risk of heparin-induced 
thrombocytopenia and thrombosis (HITT)
• HITT should be suspected if platelet counts 
drop by more than 50% from baseline after 
heparin therapy is begun.
Anticoagulation and CRRT
Trisodium Citrate
• Inhibits clotting by binding calcium, a key 
cofactor in the clotting cascade.
• Eliminates the risk of HITT, and does not cause 
systemic anticoagulation.
• A calcium chloride infusion is administered to 
the patient to replace the calcium bound by the 
citrate.
Anticoagulation and CRRT
No anticoagulation
• It may be safer to avoid anticoagulation:  
“losing the filter is better than losing the 
patient!”
• Contraindicated in patients with:
 Platelet count <50,000/mm3
 INR > 2.0
 aPTT > 60 seconds
 Active bleed
 Severe hepatic dysfunction
Anticoagulation and CRRT
Slow Continuous Ultrafiltration (SCUF)
• Uses no dialysate or replacement fluid.
Continuous VenoVenous Hemofiltration (CVVH)
• Uses replacement fluids, but no dialysate.
Continuous VenoVenous HemoDialysis (CVVHD)
• Dialysate is run, but no replacement fluid.
• Very similar to traditional hemodialysis.
Continuous VenoVenous HemoDiaFiltration (CVVHDF)
• Uses both dialysate and replacement fluid.
• Most flexible of all therapies.
Types of CRRT Therapy
• Bleeding
• Hypothermia
• Electrolyte imbalances
• Acid-Base imbalances
• Infection
Complications of CRRT
• CRRT therapies clear most renally excreted 
drugs as efficiently as patients with normal 
renal function.
• Doses do not need to be empirically reduced for 
renal dysfunction while CRRT is running.
• Be aware that doses may need to be increased 
when CRRT is started, and decreased when 
CRRT is discontinued.
Appropriate Dosing of Medications
• The critical care nurse is responsible for administering 
CRRT and assessing the patient’s response to therapy.
• The nurse is also the primary communicator in the 
CRRT process.
• The pharmacist is responsible for the compounding of 
the various solutions and medications required.
• The pharmacist, as part of the multidisciplinary team, 
assists in adjusting the doses and formulas of the 
various therapies.
Conclusion
Products provided by pharmacy in the 
provisionof CRRT:
• Dialysate
• Replacement fluids
• Anticoagulation (heparin or citrate)
• Calcium chloride (if citrate is used)
• TPN
Conclusion
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